Sograzepide

• CAT Number: R020079
• CAS Number: 155488-25-8
• Molecular Formula: C28H30N6O3
• Molecular Weight: 498.58
• Purity: ≥95%
• Synonyms: 1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea
• InChI: InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37)/t25-/m0/s1
• InChIKey: YDZYKNJZCVIKPP-VWLOTQADSA-N
• SMILES: CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4

Sograzepide(CAT: R020079) is a pharmaceutical compound that acts as a cholecystokinin (CCK) receptor antagonist. It is specifically known for its ability to block the CCK-A receptors, which are primarily located in the gastrointestinal tract. By inhibiting these receptors, Sograzepide can influence digestive processes, including the secretion of digestive enzymes and the regulation of appetite. This makes it a compound of interest in research related to gastrointestinal disorders, appetite regulation, and conditions like irritable bowel syndrome (IBS) or pancreatic diseases. Though its clinical development has been limited, Sograzepide has contributed to the understanding of CCK’s role in digestive physiology and the potential therapeutic applications of CCK antagonists.